메뉴 건너뛰기




Volumn 29, Issue 7, 2012, Pages 775-796

Erratum: Progression of cutaneous melanoma: Implications for treatment (Clinical and Experimental Metastasis DOI: 10.1007/s10585-012-9521-1);Progression of cutaneous melanoma: Implications for treatment

Author keywords

Biomarkers; Melanoma; Metastasis; Progression

Indexed keywords


EID: 84868212800     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9535-8     Document Type: Erratum
Times cited : (33)

References (151)
  • 2
    • 33845329568 scopus 로고    scopus 로고
    • Markers and tissue resources for melanoma: Meeting report
    • Becker D, Mihm MC, Hewitt SM et al (2006) Markers and tissue resources for melanoma: Meeting report. Cancer Res 66: 10652-10657
    • (2006) Cancer Res , vol.66 , pp. 10652-10657
    • Becker, D.1    Mihm, M.C.2    Hewitt, S.M.3
  • 4
    • 83755196805 scopus 로고    scopus 로고
    • BRAF inhibitors and melanoma
    • Flaherty KT (2011) BRAF inhibitors and melanoma. Cancer J 17:505-511
    • (2011) Cancer J , vol.17 , pp. 505-511
    • Flaherty, K.T.1
  • 5
    • 74949143594 scopus 로고    scopus 로고
    • Final version of 2009 AJCC melanoma staging and classification
    • Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
    • (2009) J Clin Oncol , vol.27 , pp. 6199-6206
    • Balch, C.M.1    Gershenwald, J.E.2    Soong, S.J.3
  • 6
    • 79953897102 scopus 로고    scopus 로고
    • Cutaneous melanoma: A model to study cancer metastasis
    • Leong SP, Gershenwald JE, Soong SJ et al (2011) Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103:538-549
    • (2011) J Surg Oncol , vol.103 , pp. 538-549
    • Leong, S.P.1    Gershenwald, J.E.2    Soong, S.J.3
  • 7
    • 0020508749 scopus 로고
    • Modulation of the metastatic capability in B16 melanoma by cell shape
    • Raz A, Ben-Ze'ev A (1983) Modulation of the metastatic capability in B16 melanoma by cell shape. Science 221:1307-1310
    • (1983) Science , vol.221 , pp. 1307-1310
    • Raz A Ben-Ze'ev, A.1
  • 8
    • 33751252276 scopus 로고    scopus 로고
    • Cancer metastasis: Building a framework
    • Gupta GP, Massague J (2006) Cancer metastasis: Building a framework. Cell 127:679-695
    • (2006) Cell , vol.127 , pp. 679-695
    • Gupta, G.P.1    Massague, J.2
  • 9
    • 80054686286 scopus 로고    scopus 로고
    • Tumor metastasis: Molecular insights and evolving paradigms
    • Valastyan S, Weinberg RA (2011) Tumor metastasis: Molecular insights and evolving paradigms. Cell 147:275-292
    • (2011) Cell , vol.147 , pp. 275-292
    • Valastyan, S.1    Weinberg, R.A.2
  • 10
    • 83455171909 scopus 로고    scopus 로고
    • Betacatenin signaling controls metastasis in Braf-activated Ptendeficient melanomas
    • Damsky WE, Curley DP, Santhanakrishnan M et al (2011) betacatenin signaling controls metastasis in Braf-activated Ptendeficient melanomas. Cancer Cell 20:741-754
    • (2011) Cancer Cell , vol.20 , pp. 741-754
    • Damsky, W.E.1    Curley, D.P.2    Santhanakrishnan, M.3
  • 11
    • 0038481970 scopus 로고    scopus 로고
    • The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited
    • Fidler IJ (2003) The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458
    • (2003) Nat Rev Cancer , vol.3 , pp. 453-458
    • Fidler, I.J.1
  • 12
    • 0242456170 scopus 로고    scopus 로고
    • Axis of evil: Molecular mechanisms of cancer metastasis
    • Bogenrieder T, Herlyn M (2003) Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 22:6524-6536
    • (2003) Oncogene , vol.22 , pp. 6524-6536
    • Bogenrieder, T.1    Herlyn, M.2
  • 13
    • 0028841186 scopus 로고
    • Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of beta 1 integrins
    • Mortarini R, Gismondi A, Maggioni A et al (1995) Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of beta 1 integrins. Cancer Res 55:4702-4710
    • (1995) Cancer Res , vol.55 , pp. 4702-4710
    • Mortarini, R.1    Gismondi, A.2    Maggioni, A.3
  • 14
    • 67650999875 scopus 로고    scopus 로고
    • The basics of epithelial-mesenchymal transition
    • Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
    • (2009) J Clin Invest , vol.119 , pp. 1420-1428
    • Kalluri, R.1    Weinberg, R.A.2
  • 15
    • 80052964920 scopus 로고    scopus 로고
    • Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?
    • Scheel C, Weinberg RA (2011) Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129:2310-2314
    • (2011) Int J Cancer , vol.129 , pp. 2310-2314
    • Scheel, C.1    Weinberg, R.A.2
  • 16
    • 78649445049 scopus 로고    scopus 로고
    • Isolation of tumorigenic circulating melanoma cells
    • Ma J, Lin JY, Alloo A et al (2010) Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402:711-717
    • (2010) Biochem Biophys Res Commun , vol.402 , pp. 711-717
    • Ma, J.1    Lin, J.Y.2    Alloo, A.3
  • 17
    • 0346728596 scopus 로고    scopus 로고
    • Determinants of BRAF mutations in primary melanomas
    • Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890
    • (2003) J Natl Cancer Inst , vol.95 , pp. 1878-1890
    • Maldonado, J.L.1    Fridlyand, J.2    Patel, H.3
  • 18
    • 33749021085 scopus 로고    scopus 로고
    • Somatic activation of KIT in distinct subtypes of melanoma
    • Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346
    • (2006) J Clin Oncol , vol.24 , pp. 4340-4346
    • Curtin, J.A.1    Busam, K.2    Pinkel, D.3
  • 19
    • 0027930910 scopus 로고
    • Actin-binding protein expression in benign and malignant melanocytic proliferations
    • Bouffard D, Duncan LM, Howard CA et al (1994) Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol 25:709-714
    • (1994) Hum Pathol , vol.25 , pp. 709-714
    • Bouffard, D.1    Duncan, L.M.2    Howard, C.A.3
  • 20
    • 13044277567 scopus 로고    scopus 로고
    • Progression-related expression of beta3 integrin in melanomas and nevi
    • Van Belle PA, Elenitsas R, Satyamoorthy K et al (1999) Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30:562-567
    • (1999) Hum Pathol , vol.30 , pp. 562-567
    • Van Belle, P.A.1    Elenitsas, R.2    Satyamoorthy, K.3
  • 21
    • 22744438812 scopus 로고    scopus 로고
    • Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/ CD61): An important mechanism mediating melanoma cell adhesion to activated endothelium
    • Saalbach A, Wetzel A, Haustein UF et al (2005) Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/ CD61): An important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 24:4710-4720
    • (2005) Oncogene , vol.24 , pp. 4710-4720
    • Saalbach, A.1    Wetzel, A.2    Haustein, U.F.3
  • 22
    • 0032749387 scopus 로고    scopus 로고
    • Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression
    • Hofmann UB, Westphal JR, Waas ET et al (1999) Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 81:774-782
    • (1999) Br J Cancer , vol.81 , pp. 774-782
    • Hofmann, U.B.1    Westphal, J.R.2    Waas, E.T.3
  • 23
    • 0035087474 scopus 로고    scopus 로고
    • Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis
    • Bodey B, Bodey B Jr, Siegel SE et al (2001) Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis. In Vivo (Athens, Greece) 15:57-64
    • (2001) Vivo (Athens, Greece , vol.15 , pp. 57-64
    • Bodey, B.1    Bodey Jr., B.2    Siegel, S.E.3
  • 24
    • 84858793024 scopus 로고    scopus 로고
    • Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma
    • Chen Y, Huang L, Yu J (2012) Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol 39:339-343
    • (2012) J Dermatol , vol.39 , pp. 339-343
    • Chen, Y.1    Huang, L.2    Yu, J.3
  • 25
    • 84860273222 scopus 로고    scopus 로고
    • MDA-9/syntenin: A positive gatekeeper of melanoma metastasis
    • Das SK, Bhutia SK, Kegelman TP et al (2012) MDA-9/syntenin: A positive gatekeeper of melanoma metastasis. Front Biosci 17: 1-15
    • (2012) Front Biosci , vol.17 , pp. 1-15
    • Das, S.K.1    Bhutia, S.K.2    Kegelman, T.P.3
  • 26
    • 84862801153 scopus 로고    scopus 로고
    • Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway
    • Lu Z, Lu N, Li C et al (2012) Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209:211-220
    • (2012) Toxicol Lett , vol.209 , pp. 211-220
    • Lu, Z.1    Lu, N.2    Li, C.3
  • 27
    • 33745288277 scopus 로고    scopus 로고
    • Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene
    • Kim M, Gans JD, Nogueira C et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281
    • (2006) Cell , vol.125 , pp. 1269-1281
    • Kim, M.1    Gans, J.D.2    Nogueira, C.3
  • 28
    • 84863230202 scopus 로고    scopus 로고
    • SOX2 contributes to melanoma cell invasion
    • Girouard SD, Laga AC, Mihm MC et al (2012) SOX2 contributes to melanoma cell invasion. Lab Investig 92:362-370
    • (2012) Lab Investig , vol.92 , pp. 362-370
    • Girouard, S.D.1    Laga, A.C.2    Mihm, M.C.3
  • 29
    • 79952724400 scopus 로고    scopus 로고
    • SOX2 and nestin expression in human melanoma: An immunohistochemical and experimental study
    • Laga AC, Zhan Q, Weishaupt C et al (2011) SOX2 and nestin expression in human melanoma: An immunohistochemical and experimental study. Exp Dermatol 20:339-345
    • (2011) Exp Dermatol , vol.20 , pp. 339-345
    • Laga, A.C.1    Zhan, Q.2    Weishaupt, C.3
  • 30
    • 76149092522 scopus 로고    scopus 로고
    • Expression of the embryonic stem cell transcription factor SOX2 in human skin: Relevance to melanocyte and merkel cell biology
    • Laga AC, Lai CY, Zhan Q et al (2010) Expression of the embryonic stem cell transcription factor SOX2 in human skin: Relevance to melanocyte and merkel cell biology. Am J Pathol 176:903-913
    • (2010) Am J Pathol , vol.176 , pp. 903-913
    • Laga, A.C.1    Lai, C.Y.2    Zhan, Q.3
  • 31
    • 0036163492 scopus 로고    scopus 로고
    • Melanoma-stroma interactions: Structural and functional aspects
    • Ruiter D, Bogenrieder T, Elder D et al (2002) Melanoma-stroma interactions: Structural and functional aspects. Lancet Oncol 3:35-43
    • (2002) Lancet Oncol , vol.3 , pp. 35-43
    • Ruiter, D.1    Bogenrieder, T.2    Elder, D.3
  • 32
    • 70350072797 scopus 로고    scopus 로고
    • Stromal expression of MMP-13 is required for melanoma invasion and metastasis
    • Zigrino P, Kuhn I, Bauerle T et al (2009) Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Investig Dermatol 129:2686-2693
    • (2009) J Investig Dermatol , vol.129 , pp. 2686-2693
    • Zigrino, P.1    Kuhn, I.2    Bauerle, T.3
  • 33
    • 12544253705 scopus 로고    scopus 로고
    • Malignant melanoma and HIV infection-aggressive course despite immune reconstitution
    • Hoffmann C, Horst HA, Weichenthal M et al (2005) Malignant melanoma and HIV infection-aggressive course despite immune reconstitution. Onkologie 28:35-37
    • (2005) Onkologie , vol.28 , pp. 35-37
    • Hoffmann, C.1    Horst, H.A.2    Weichenthal, M.3
  • 34
    • 79955562722 scopus 로고    scopus 로고
    • Prognostic geneexpression signature of carcinoma-associated fibroblasts in nonsmall cell lung cancer
    • Navab R, Strumpf D, Bandarchi B et al (2011) Prognostic geneexpression signature of carcinoma-associated fibroblasts in nonsmall cell lung cancer. Proc Natl Acad Sci USA 108:7160-7165
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 7160-7165
    • Navab, R.1    Strumpf, D.2    Bandarchi, B.3
  • 35
    • 72949083968 scopus 로고    scopus 로고
    • Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells
    • Navab R, Liu J, Seiden-Long I et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11:1292-1300
    • (2009) Neoplasia , vol.11 , pp. 1292-1300
    • Navab, R.1    Liu, J.2    Seiden-Long, I.3
  • 36
    • 58149102321 scopus 로고    scopus 로고
    • Molecular basis of metastasis
    • Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814-2823
    • (2008) N Engl J Med , vol.359 , pp. 2814-2823
    • Chiang, A.C.1    Massague, J.2
  • 37
    • 37649001973 scopus 로고    scopus 로고
    • ID genes mediate tumor reinitiation during breast cancer lung metastasis
    • Gupta GP, Perk J, Acharyya S et al (2007) ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 104:19506-19511
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 19506-19511
    • Gupta, G.P.1    Perk, J.2    Acharyya, S.3
  • 38
    • 44449084242 scopus 로고    scopus 로고
    • Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response
    • Swarbrick A, Roy E, Allen T et al (2008) Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 105:5402-5407
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 5402-5407
    • Swarbrick, A.1    Roy, E.2    Allen, T.3
  • 39
    • 28644432204 scopus 로고    scopus 로고
    • VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
    • Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827
    • (2005) Nature , vol.438 , pp. 820-827
    • Kaplan, R.N.1    Riba, R.D.2    Zacharoulis, S.3
  • 40
    • 77949952457 scopus 로고    scopus 로고
    • Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development
    • Mihm MC Jr, Nelson JS (2010) Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol 37(Suppl 1):83-87
    • (2010) J Cutan Pathol , vol.37 , Issue.SUPPL. 1 , pp. 83-87
    • Mihm Jr., M.C.1    Nelson, J.S.2
  • 41
    • 33846239456 scopus 로고    scopus 로고
    • Beyond tumorigenesis: Cancer stem cells in metastasis
    • Li F, Tiede B, Massague J et al (2007) Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 17:3-14
    • (2007) Cell Res , vol.17 , pp. 3-14
    • Li, F.1    Tiede, B.2    Massague, J.3
  • 43
    • 0030967081 scopus 로고    scopus 로고
    • Chemokines induce migrational responses in human breast carcinoma cell lines
    • Youngs SJ, Ali SA, Taub DD et al (1997) Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71:257-266
    • (1997) Int J Cancer , vol.71 , pp. 257-266
    • Youngs, S.J.1    Ali, S.A.2    Taub, D.D.3
  • 44
    • 33745077057 scopus 로고    scopus 로고
    • Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy
    • Shu S, Cochran AJ, Huang RR et al (2006) Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy. Cancer Metastasis Rev 25:233-242
    • (2006) Cancer Metastasis Rev , vol.25 , pp. 233-242
    • Shu, S.1    Cochran, A.J.2    Huang, R.R.3
  • 46
    • 2542612840 scopus 로고    scopus 로고
    • Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
    • Kawada K, Sonoshita M, Sakashita H et al (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64:4010-4017
    • (2004) Cancer Res , vol.64 , pp. 4010-4017
    • Kawada, K.1    Sonoshita, M.2    Sakashita, H.3
  • 48
    • 84862824075 scopus 로고    scopus 로고
    • AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome
    • Hoshimoto S, Kuo CT, Chong KK et al (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Investig Dermatol 132: 1689-1697
    • (2012) J Investig Dermatol , vol.132 , pp. 1689-1697
    • Hoshimoto, S.1    Kuo, C.T.2    Chong, K.K.3
  • 49
    • 63449140854 scopus 로고    scopus 로고
    • CpG island methylator phenotype predicts progression of malignant melanoma
    • Tanemura A, Terando AM, Sim MS et al (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801-1807
    • (2009) Clin Cancer Res , vol.15 , pp. 1801-1807
    • Tanemura, A.1    Terando, A.M.2    Sim, M.S.3
  • 50
    • 16444373352 scopus 로고    scopus 로고
    • Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells
    • Mori T, Kim J, Yamano T et al (2005) Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65:1800-1807
    • (2005) Cancer Res , vol.65 , pp. 1800-1807
    • Mori, T.1    Kim, J.2    Yamano, T.3
  • 51
    • 33746159061 scopus 로고    scopus 로고
    • Estrogen receptoralpha methylation predicts melanoma progression
    • Mori T, Martinez SR, O'Day SJ et al (2006) Estrogen receptoralpha methylation predicts melanoma progression. Cancer Res 66:6692-6698
    • (2006) Cancer Res , vol.66 , pp. 6692-6698
    • Mori, T.1    Martinez, S.R.2    O'Day, S.J.3
  • 52
    • 74349098151 scopus 로고    scopus 로고
    • High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma
    • Goto Y, Arigami T, Murali R et al (2010) High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res 23:137-140
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 137-140
    • Goto, Y.1    Arigami, T.2    Murali, R.3
  • 53
    • 50349103346 scopus 로고    scopus 로고
    • Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes
    • Goto Y, Ferrone S, Arigami T et al (2008) Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 14:3401-3407
    • (2008) Clin Cancer Res , vol.14 , pp. 3401-3407
    • Goto, Y.1    Ferrone, S.2    Arigami, T.3
  • 54
    • 2542522279 scopus 로고    scopus 로고
    • Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
    • Hoon DS, Spugnardi M, Kuo C et al (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-4022
    • (2004) Oncogene , vol.23 , pp. 4014-4022
    • Hoon, D.S.1    Spugnardi, M.2    Kuo, C.3
  • 55
    • 65649092616 scopus 로고    scopus 로고
    • Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma
    • Kitago M, Martinez SR, Nakamura T et al (2009) Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 15:2988-2994
    • (2009) Clin Cancer Res , vol.15 , pp. 2988-2994
    • Kitago, M.1    Martinez, S.R.2    Nakamura, T.3
  • 56
    • 79952421239 scopus 로고    scopus 로고
    • Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma
    • Nguyen T, Kuo C, Nicholl MB et al (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma. Epigenetics 6:388-394
    • (2011) Epigenetics , vol.6 , pp. 388-394
    • Nguyen, T.1    Kuo, C.2    Nicholl, M.B.3
  • 57
    • 44249087640 scopus 로고    scopus 로고
    • Quantitative analysis of methylation of genomic loci in earlystage rectal cancer predicts distant recurrence
    • de Maat MF, van de Velde CJ, van der Werff MP et al (2008) Quantitative analysis of methylation of genomic loci in earlystage rectal cancer predicts distant recurrence. J Clin Oncol 26: 2327-2335
    • (2008) J Clin Oncol , vol.26 , pp. 2327-2335
    • De Maat, M.F.1    Van De Velde, C.J.2    Van Der Werff, M.P.3
  • 58
    • 20944437231 scopus 로고    scopus 로고
    • The gene expression signatures of melanoma progression
    • Haqq C, Nosrati M, Sudilovsky D et al (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-6097
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 6092-6097
    • Haqq, C.1    Nosrati, M.2    Sudilovsky, D.3
  • 59
    • 65549107322 scopus 로고    scopus 로고
    • A multimarker assay to distinguish malignant melanomas from benign nevi
    • Kashani-Sabet M, Rangel J, Torabian S et al (2009) A multimarker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 106:6268-6272
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 6268-6272
    • Kashani-Sabet, M.1    Rangel, J.2    Torabian, S.3
  • 60
    • 72549092919 scopus 로고    scopus 로고
    • A multimarker prognostic assay for primary cutaneous melanoma
    • Kashani-Sabet M, Venna S, Nosrati M et al (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987-6992
    • (2009) Clin Cancer Res , vol.15 , pp. 6987-6992
    • Kashani-Sabet, M.1    Venna, S.2    Nosrati, M.3
  • 61
    • 33750588921 scopus 로고    scopus 로고
    • Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma
    • Rangel J, Torabian S, Shaikh L et al (2006) Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24:4565-4569
    • (2006) J Clin Oncol , vol.24 , pp. 4565-4569
    • Rangel, J.1    Torabian, S.2    Shaikh, L.3
  • 62
    • 37449031252 scopus 로고    scopus 로고
    • Osteopontin as a molecular prognostic marker for melanoma
    • Rangel J, Nosrati M, Torabian S et al (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150
    • (2008) Cancer , vol.112 , pp. 144-150
    • Rangel, J.1    Nosrati, M.2    Torabian, S.3
  • 63
    • 49249129411 scopus 로고    scopus 로고
    • Novel role for RGS1 in melanoma progression
    • Rangel J, Nosrati M, Leong SP et al (2008) Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32:1207-1212
    • (2008) Am J Surg Pathol , vol.32 , pp. 1207-1212
    • Rangel, J.1    Nosrati, M.2    Leong, S.P.3
  • 64
    • 0016776479 scopus 로고
    • Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
    • Mastrangelo MJ, Bellet RE, Berkelhammer J et al (1975) Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36:1305-1308
    • (1975) Cancer , vol.36 , pp. 1305-1308
    • Mastrangelo, M.J.1    Bellet, R.E.2    Berkelhammer, J.3
  • 65
    • 1842582038 scopus 로고    scopus 로고
    • Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group
    • Agarwala SS, Neuberg D, Park Y et al (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group. Cancer 100:1692-1698
    • (2004) Cancer , vol.100 , pp. 1692-1698
    • Agarwala, S.S.1    Neuberg, D.2    Park, Y.3
  • 66
    • 77952238515 scopus 로고    scopus 로고
    • A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma
    • Bedikian AY, Richards J, Kharkevitch D et al (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20:218-226
    • (2010) Melanoma Res , vol.20 , pp. 218-226
    • Bedikian, A.Y.1    Richards, J.2    Kharkevitch, D.3
  • 67
    • 73349133717 scopus 로고    scopus 로고
    • Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
    • Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763-5771
    • (2009) J Clin Oncol , vol.27 , pp. 5763-5771
    • Senzer, N.N.1    Kaufman, H.L.2    Amatruda, T.3
  • 68
    • 56849112041 scopus 로고    scopus 로고
    • Chemoablation of metastatic melanoma using intralesional Rose Bengal
    • Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18:405-411
    • (2008) Melanoma Res , vol.18 , pp. 405-411
    • Thompson, J.F.1    Hersey, P.2    Wachter, E.3
  • 69
    • 49649115107 scopus 로고    scopus 로고
    • Therapy for unresectable recurrent and in-transit extremity melanoma
    • Gimbel MI, Delman KA, Zager JS (2008) Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 15:225-232
    • (2008) Cancer Control , vol.15 , pp. 225-232
    • Gimbel, M.I.1    Delman, K.A.2    Zager, J.S.3
  • 70
    • 48149092966 scopus 로고    scopus 로고
    • Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
    • Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195-2205
    • (2008) Ann Surg Oncol , vol.15 , pp. 2195-2205
    • Beasley, G.M.1    Petersen, R.P.2    Yoo, J.3
  • 71
    • 0036210893 scopus 로고    scopus 로고
    • Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma
    • Lindner P, Doubrovsky A, Kam PC et al (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127-136
    • (2002) Ann Surg Oncol , vol.9 , pp. 127-136
    • Lindner, P.1    Doubrovsky, A.2    Kam, P.C.3
  • 72
    • 55149102005 scopus 로고    scopus 로고
    • Outcomes following isolated limb infusion for melanoma. A 14-year experience
    • Kroon HM, Moncrieff M, Kam PC et al (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15:3003-3013
    • (2008) Ann Surg Oncol , vol.15 , pp. 3003-3013
    • Kroon, H.M.1    Moncrieff, M.2    Kam, P.C.3
  • 73
    • 33748968131 scopus 로고    scopus 로고
    • Hyperthermic regional perfusion for melanoma and sarcoma of the limbs
    • Fraker DL (1999) Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 36:841-907
    • (1999) Curr Probl Surg , vol.36 , pp. 841-907
    • Fraker, D.L.1
  • 74
    • 64949083543 scopus 로고    scopus 로고
    • A multiinstitutional experience of isolated limb infusion: Defining response and toxicity in the US
    • discussion 715-717
    • Beasley GM, Caudle A, Petersen RP et al (2009) A multiinstitutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 208:706-715; discussion 715-717
    • (2009) J Am Coll Surg , vol.208 , pp. 706-715
    • Beasley, G.M.1    Caudle, A.2    Petersen, R.P.3
  • 75
    • 68949207802 scopus 로고    scopus 로고
    • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis
    • Santillan AA, Delman KA, Beasley GM et al (2009) Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis. Ann Surg Oncol 16:2570-2578
    • (2009) Ann Surg Oncol , vol.16 , pp. 2570-2578
    • Santillan, A.A.1    Delman, K.A.2    Beasley, G.M.3
  • 76
    • 0020365748 scopus 로고
    • Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
    • Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910
    • (1982) Eur J Cancer Clin Oncol , vol.18 , pp. 905-910
    • Wieberdink, J.1    Benckhuysen, C.2    Braat, R.P.3
  • 77
    • 84862554871 scopus 로고    scopus 로고
    • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities
    • Chai CY, Deneve JL, Beasley GM et al (2012) A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 19:1637-1643
    • (2012) Ann Surg Oncol , vol.19 , pp. 1637-1643
    • Chai, C.Y.1    Deneve, J.L.2    Beasley, G.M.3
  • 78
    • 79952781372 scopus 로고    scopus 로고
    • Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma
    • Beasley GM, Riboh JC, Augustine CK et al (2011) Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 29:1210-1215
    • (2011) J Clin Oncol , vol.29 , pp. 1210-1215
    • Beasley, G.M.1    Riboh, J.C.2    Augustine, C.K.3
  • 79
    • 77954572289 scopus 로고    scopus 로고
    • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    • Augustine CK, Toshimitsu H, Jung SH et al (2010) Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 9:2090-2101
    • (2010) Mol Cancer Ther , vol.9 , pp. 2090-2101
    • Augustine, C.K.1    Toshimitsu, H.2    Jung, S.H.3
  • 80
    • 0028512070 scopus 로고
    • Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study
    • Curley SA, Newman RA, Dougherty TB et al (1994) Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study. Ann Surg Oncol 1:389-399
    • (1994) Ann Surg Oncol , vol.1 , pp. 389-399
    • Curley, S.A.1    Newman, R.A.2    Dougherty, T.B.3
  • 81
    • 20644434717 scopus 로고    scopus 로고
    • Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies
    • Pingpank JF, Libutti SK, Chang R et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465-3474
    • (2005) J Clin Oncol , vol.23 , pp. 3465-3474
    • Pingpank, J.F.1    Libutti, S.K.2    Chang, R.3
  • 82
    • 0346333288 scopus 로고    scopus 로고
    • Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver
    • Alexander HR Jr, Libutti SK, Pingpank JF et al (2003) Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9: 6343-6349
    • (2003) Clin Cancer Res , vol.9 , pp. 6343-6349
    • Alexander Jr., H.R.1    Libutti, S.K.2    Pingpank, J.F.3
  • 83
    • 79954601182 scopus 로고    scopus 로고
    • A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma
    • June 2010
    • Pingpank JF, Hughes MS, Alexander HR et al (2010) A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. In: Presented at the American Society of Clinical Oncology, June 2010
    • (2010) Presented at the American Society of Clinical Oncology
    • Pingpank, J.F.1    Hughes, M.S.2    Alexander, H.R.3
  • 84
    • 84873081713 scopus 로고    scopus 로고
    • Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients with melanoma liver metastases-Efficacy update of the phase 3 trial (NCT00324727
    • Stockholm, Sweden, Sept 2011
    • Pingpank JF, Hughes M, Alexander HR et al (2011) Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients with melanoma liver metastases-efficacy update of the phase 3 trial (NCT00324727). In: European Multidisciplinary Cancer Congress. Stockholm, Sweden, Sept 2011
    • (2011) European Multidisciplinary Cancer Congress
    • Pingpank, J.F.1    Hughes, M.2    Alexander, H.R.3
  • 85
    • 84868213257 scopus 로고    scopus 로고
    • Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients (pts) with melanoma liver metastases: Updated data from the phase III trial
    • Zager JS, JF. P (2011) Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients (pts) with melanoma liver metastases: Updated data from the phase III trial. In: International Melanoma Centers Meeting, Tampa, Florida. Pigment Cell Melanoma Res 24:1010-1011
    • (2011) International Melanoma Centers Meeting, Tampa, Florida. Pigment Cell Melanoma Res , vol.24 , pp. 1010-1011
    • Zager, J.S.1    Jf, P.2
  • 86
    • 0035880957 scopus 로고    scopus 로고
    • Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    • Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634
    • (2001) J Clin Oncol , vol.19 , pp. 3622-3634
    • Balch, C.M.1    Soong, S.J.2    Gershenwald, J.E.3
  • 87
    • 33749618081 scopus 로고    scopus 로고
    • Clinical relevance of melanoma micrometastases (?0.1 mm) in sentinel nodes: Are these nodes to be considered negative?
    • van Akkooi AC, de Wilt JH, Verhoef C et al (2006) Clinical relevance of melanoma micrometastases (?0.1 mm) in sentinel nodes: Are these nodes to be considered negative? Ann Oncol 17:1578-1585
    • (2006) Ann Oncol , vol.17 , pp. 1578-1585
    • Van Akkooi, A.C.1    De Wilt, J.H.2    Verhoef, C.3
  • 88
    • 58149375115 scopus 로고    scopus 로고
    • Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes
    • van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248:949-955
    • (2008) Ann Surg , vol.248 , pp. 949-955
    • Van Akkooi, A.C.1    Nowecki, Z.I.2    Voit, C.3
  • 89
    • 0030966641 scopus 로고    scopus 로고
    • Optimal selective sentinel lymph node dissection in primary malignant melanoma
    • discussion 673
    • Leong SP, Steinmetz I, Habib FA et al (1997) Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 132:666-672; discussion 673
    • (1997) Arch Surg , vol.132 , pp. 666-672
    • Leong, S.P.1    Steinmetz, I.2    Habib, F.A.3
  • 90
    • 3843119131 scopus 로고    scopus 로고
    • Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma
    • Leong SP (2004) Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma. Curr Treat Options Oncol 5:185-194
    • (2004) Curr Treat Options Oncol , vol.5 , pp. 185-194
    • Leong, S.P.1
  • 91
    • 0036895061 scopus 로고    scopus 로고
    • Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy
    • Ranieri JM, Wagner JD, Azuaje R et al (2002) Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9:975-981
    • (2002) Ann Surg Oncol , vol.9 , pp. 975-981
    • Ranieri, J.M.1    Wagner, J.D.2    Azuaje, R.3
  • 92
    • 0041784818 scopus 로고    scopus 로고
    • The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance?
    • Carlson GW, Murray DR, Lyles RH et al (2003) The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? Ann Surg Oncol 10:575-581
    • (2003) Ann Surg Oncol , vol.10 , pp. 575-581
    • Carlson, G.W.1    Murray, D.R.2    Lyles, R.H.3
  • 93
    • 0037269753 scopus 로고    scopus 로고
    • Prediction of nonsentinel lymph node status in melanoma
    • Reeves ME, Delgado R, Busam KJ et al (2003) Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10:27-31
    • (2003) Ann Surg Oncol , vol.10 , pp. 27-31
    • Reeves, M.E.1    Delgado, R.2    Busam, K.J.3
  • 94
    • 4644309225 scopus 로고    scopus 로고
    • Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma
    • Lee JH, Essner R, Torisu-Itakura H et al (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma. J Clin Oncol 22:3677-3684
    • (2004) J Clin Oncol , vol.22 , pp. 3677-3684
    • Lee, J.H.1    Essner, R.2    Torisu-Itakura, H.3
  • 95
    • 4644260554 scopus 로고    scopus 로고
    • Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma
    • Scolyer RA, Li LX, McCarthy SW et al (2004) Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 122:532-539
    • (2004) Am J Clin Pathol , vol.122 , pp. 532-539
    • Scolyer, R.A.1    Li, L.X.2    McCarthy, S.W.3
  • 96
    • 20544433657 scopus 로고    scopus 로고
    • Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma
    • Sabel MS, Griffith K, Sondak VK et al (2005) Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201:37-47
    • (2005) J Am Coll Surg , vol.201 , pp. 37-47
    • Sabel, M.S.1    Griffith, K.2    Sondak, V.K.3
  • 97
    • 34250679266 scopus 로고    scopus 로고
    • Sentinel lymph node biopsy in melanoma: A micromorphometric study relating to prognosis and completion lymph node dissection
    • Debarbieux S, Duru G, Dalle S et al (2007) Sentinel lymph node biopsy in melanoma: A micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 157:58-67
    • (2007) Br J Dermatol , vol.157 , pp. 58-67
    • Debarbieux, S.1    Duru, G.2    Dalle, S.3
  • 98
    • 34648817394 scopus 로고    scopus 로고
    • Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma
    • Scheri RP, Essner R, Turner RR et al (2007) Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14:2861-2866
    • (2007) Ann Surg Oncol , vol.14 , pp. 2861-2866
    • Scheri, R.P.1    Essner, R.2    Turner, R.R.3
  • 99
    • 34548537468 scopus 로고    scopus 로고
    • Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma
    • discussion 678-679
    • Page AJ, Carlson GW, Delman KA et al (2007) Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg 73:674-678; discussion 678-679
    • (2007) Am Surg , vol.73 , pp. 674-678
    • Page, A.J.1    Carlson, G.W.2    Delman, K.A.3
  • 100
    • 47149097293 scopus 로고    scopus 로고
    • Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients
    • Glumac N, Hocevar M, Zadnik V et al (2008) Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol 98:46-48
    • (2008) J Surg Oncol , vol.98 , pp. 46-48
    • Glumac, N.1    Hocevar, M.2    Zadnik, V.3
  • 101
    • 50049128948 scopus 로고    scopus 로고
    • Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node
    • Rossi CR, De Salvo GL, Bonandini E et al (2008) Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 15:1202-1210
    • (2008) Ann Surg Oncol , vol.15 , pp. 1202-1210
    • Rossi, C.R.1    De Salvo, G.L.2    Bonandini, E.3
  • 102
    • 50049112105 scopus 로고    scopus 로고
    • Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    • Frankel TL, Griffith KA, Lowe L et al (2008) Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 15:2403-2411
    • (2008) Ann Surg Oncol , vol.15 , pp. 2403-2411
    • Frankel, T.L.1    Griffith, K.A.2    Lowe, L.3
  • 103
    • 44949097220 scopus 로고    scopus 로고
    • The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-A retrospective analysis of 392 cases
    • Guggenheim M, Dummer R, Jung FJ et al (2008) The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-a retrospective analysis of 392 cases. Br J Cancer 98:1922-1928
    • (2008) Br J Cancer , vol.98 , pp. 1922-1928
    • Guggenheim, M.1    Dummer, R.2    Jung, F.J.3
  • 104
    • 52049107850 scopus 로고    scopus 로고
    • Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma
    • Gershenwald JE, Andtbacka RH, Prieto VG et al (2008) Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26:4296-4303
    • (2008) J Clin Oncol , vol.26 , pp. 4296-4303
    • Gershenwald, J.E.1    Andtbacka, R.H.2    Prieto, V.G.3
  • 105
    • 68949086788 scopus 로고    scopus 로고
    • Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node
    • van der Ploeg IM, Kroon BB, Antonini N et al (2009) Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg 250: 301-304
    • (2009) Ann Surg , vol.250 , pp. 301-304
    • Van Der Ploeg, I.M.1    Kroon, B.B.2    Antonini, N.3
  • 106
    • 77952099173 scopus 로고    scopus 로고
    • Influence of sentinel lymph node tumor burden on survival in melanoma
    • Francischetto T, Spector N, Neto Rezende JF et al (2010) Influence of sentinel lymph node tumor burden on survival in melanoma. Ann Surg Oncol 17:1152-1158
    • (2010) Ann Surg Oncol , vol.17 , pp. 1152-1158
    • Francischetto, T.1    Spector, N.2    Neto Rezende, J.F.3
  • 107
    • 34547631945 scopus 로고    scopus 로고
    • Prognostic significance of isolated HMB45 or Melan A positive cells in melanoma sentinel lymph nodes
    • Satzger I, Volker B, Meier A et al (2007) Prognostic significance of isolated HMB45 or Melan A positive cells in melanoma sentinel lymph nodes. Am J Surg Pathol 31:1175-1180
    • (2007) Am J Surg Pathol , vol.31 , pp. 1175-1180
    • Satzger, I.1    Volker, B.2    Meier, A.3
  • 108
    • 82955237235 scopus 로고    scopus 로고
    • Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database
    • White RL Jr, Ayers GD, Stell VH et al (2011) Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 18:3593-3600
    • (2011) Ann Surg Oncol , vol.18 , pp. 3593-3600
    • White Jr., R.L.1    Ayers, G.D.2    Stell, V.H.3
  • 109
    • 4344630988 scopus 로고    scopus 로고
    • The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement
    • Dewar DJ, Newell B, Green MA et al (2004) The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 22: 3345-3349
    • (2004) J Clin Oncol , vol.22 , pp. 3345-3349
    • Dewar, D.J.1    Newell, B.2    Green, M.A.3
  • 110
    • 0031970288 scopus 로고    scopus 로고
    • Primary therapy of malignant melanomas: Sentinel lymphadenectomy
    • Bachter D, Balda BR, Vogt H et al (1998) Primary therapy of malignant melanomas: Sentinel lymphadenectomy. Int J Dermatol 37:278-282
    • (1998) Int J Dermatol , vol.37 , pp. 278-282
    • Bachter, D.1    Balda, B.R.2    Vogt, H.3
  • 111
    • 0030930407 scopus 로고    scopus 로고
    • Sentinel node biopsy in melanoma patients: Dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance
    • discussion 793
    • Pijpers R, Borgstein PJ, Meijer S et al (1997) Sentinel node biopsy in melanoma patients: Dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 21:788-792; discussion 793
    • (1997) World J Surg , vol.21 , pp. 788-792
    • Pijpers, R.1    Borgstein, P.J.2    Meijer, S.3
  • 112
    • 0030753746 scopus 로고    scopus 로고
    • Sentinel lymph node evaluation in melanoma
    • Brady MS, Coit DG (1997) Sentinel lymph node evaluation in melanoma. Arch Dermatol 133:1014-1020
    • (1997) Arch Dermatol , vol.133 , pp. 1014-1020
    • Brady, M.S.1    Coit, D.G.2
  • 113
    • 0028052025 scopus 로고
    • The orderly progression of melanoma nodal metastases
    • Reintgen D, Cruse CW, Wells K et al (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220:759-767
    • (1994) Ann Surg , vol.220 , pp. 759-767
    • Reintgen, D.1    Cruse, C.W.2    Wells, K.3
  • 114
    • 0028788777 scopus 로고
    • The role of selective lymphadenectomy in the management of patients with malignant melanoma
    • Glass LF, Fenske NA, Messina JL et al (1995) The role of selective lymphadenectomy in the management of patients with malignant melanoma. Dermatol Surg 21:979-983
    • (1995) Dermatol Surg , vol.21 , pp. 979-983
    • Glass, L.F.1    Fenske, N.A.2    Messina, J.L.3
  • 115
    • 0029074162 scopus 로고
    • Minimal-access surgery for staging of malignant melanoma
    • discussion 659-660
    • Krag DN, Meijer SJ, Weaver DL et al (1995) Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-658; discussion 659-660
    • (1995) Arch Surg , vol.130 , pp. 654-658
    • Krag, D.N.1    Meijer, S.J.2    Weaver, D.L.3
  • 116
    • 0029038818 scopus 로고
    • Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes
    • Thompson JF, McCarthy WH, Bosch CM et al (1995) Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5:255-260
    • (1995) Melanoma Res , vol.5 , pp. 255-260
    • Thompson, J.F.1    McCarthy, W.H.2    Bosch, C.M.3
  • 117
    • 0032897292 scopus 로고    scopus 로고
    • Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients
    • Lenisa L, Santinami M, Belli F et al (1999) Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients. J Exp Clin Cancer Res 18:69-74
    • (1999) J Exp Clin Cancer Res , vol.18 , pp. 69-74
    • Lenisa, L.1    Santinami, M.2    Belli, F.3
  • 118
    • 0034662008 scopus 로고    scopus 로고
    • Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma
    • Wagner JD, Gordon MS, Chuang TY et al (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462
    • (2000) Cancer , vol.89 , pp. 453-462
    • Wagner, J.D.1    Gordon, M.S.2    Chuang, T.Y.3
  • 119
    • 0035371058 scopus 로고    scopus 로고
    • A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma
    • Starz H, Balda BR, Kramer KU et al (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110-2121
    • (2001) Cancer , vol.91 , pp. 2110-2121
    • Starz, H.1    Balda, B.R.2    Kramer, K.U.3
  • 120
    • 2942633520 scopus 로고    scopus 로고
    • Sentinel lymphonodectomy and s-classification: A successful strategy for better prediction and improvement of outcome of melanoma
    • Starz H, Siedlecki K, Balda BR (2004) Sentinel lymphonodectomy and s-classification: A successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11:162S-168S
    • (2004) Ann Surg Oncol , vol.11
    • Starz, H.1    Siedlecki, K.2    Balda, B.R.3
  • 121
    • 79957970164 scopus 로고    scopus 로고
    • Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria
    • van der Ploeg AP, van Akkooi AC, Rutkowski P et al (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206-2214
    • (2011) J Clin Oncol , vol.29 , pp. 2206-2214
    • Van Der Ploeg, A.P.1    Van Akkooi, A.C.2    Rutkowski, P.3
  • 122
    • 2942640198 scopus 로고    scopus 로고
    • Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience
    • Leong SP (2004) Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 11:192S-197S
    • (2004) Ann Surg Oncol , vol.11
    • Leong, S.P.1
  • 123
    • 84862268896 scopus 로고    scopus 로고
    • The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival
    • Baehner FL, Li R, Jenkins T et al (2012) The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 19:1034-1042
    • (2012) Ann Surg Oncol , vol.19 , pp. 1034-1042
    • Baehner, F.L.1    Li, R.2    Jenkins, T.3
  • 124
    • 0028150831 scopus 로고
    • Karnofsky Memorial Lecture. Natural history of small breast cancers
    • Hellman S (1994) Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12:2229-2234
    • (1994) J Clin Oncol , vol.12 , pp. 2229-2234
    • Hellman, S.1
  • 125
    • 33749053823 scopus 로고    scopus 로고
    • Sentinelnode biopsy or nodal observation in melanoma
    • Morton DL, Thompson JF, Cochran AJ et al (2006) Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317
    • (2006) N Engl J Med , vol.355 , pp. 1307-1317
    • Morton, D.L.1    Thompson, J.F.2    Cochran, A.J.3
  • 126
    • 34548670729 scopus 로고    scopus 로고
    • The role of sentinel lymph node biopsy in the management of melanoma
    • Amersi F, Morton DL (2007) The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 41:241-256
    • (2007) Adv Surg , vol.41 , pp. 241-256
    • Amersi, F.1    Morton, D.L.2
  • 127
    • 84655168007 scopus 로고    scopus 로고
    • Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
    • Eggermont AM, Suciu S, Testori A et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225
    • (2012) Eur J Cancer , vol.48 , pp. 218-225
    • Eggermont, A.M.1    Suciu, S.2    Testori, A.3
  • 128
    • 0347503603 scopus 로고    scopus 로고
    • Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials
    • Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
    • (2003) Lancet Oncol , vol.4 , pp. 748-759
    • Eigentler, T.K.1    Caroli, U.M.2    Radny, P.3
  • 129
    • 27844567142 scopus 로고    scopus 로고
    • Distinct sets of genetic alterations in melanoma
    • Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
    • (2005) N Engl J Med , vol.353 , pp. 2135-2147
    • Curtin, J.A.1    Fridlyand, J.2    Kageshita, T.3
  • 130
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 131
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 132
    • 84862732834 scopus 로고    scopus 로고
    • Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations
    • Greger JG, Eastman SD, Zhang V et al (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-920
    • (2012) Mol Cancer Ther , vol.11 , pp. 909-920
    • Greger, J.G.1    Eastman, S.D.2    Zhang, V.3
  • 133
    • 79960708519 scopus 로고    scopus 로고
    • Phase II, open-label, singlearm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
    • Guo J, Si L, Kong Y et al (2011) Phase II, open-label, singlearm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-2909
    • (2011) J Clin Oncol , vol.29 , pp. 2904-2909
    • Guo, J.1    Si, L.2    Kong, Y.3
  • 134
    • 84862908265 scopus 로고    scopus 로고
    • BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma
    • Kim KB, Sosman JA, Fruehauf JP et al (2012) BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30: 34-41
    • (2012) J Clin Oncol , vol.30 , pp. 34-41
    • Kim, K.B.1    Sosman, J.A.2    Fruehauf, J.P.3
  • 135
    • 80052536175 scopus 로고    scopus 로고
    • New drugs in melanoma: It's a whole new world
    • Eggermont AM, Robert C (2011) New drugs in melanoma: It's a whole new world. Eur J Cancer 47:2150-2157
    • (2011) Eur J Cancer , vol.47 , pp. 2150-2157
    • Eggermont, A.M.1    Robert, C.2
  • 136
    • 0016176253 scopus 로고
    • BCG immunotherapy of malignant melanoma: Summary of a seven-year experience
    • Morton DL, Eilber FR, Holmes EC et al (1974) BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643
    • (1974) Ann Surg , vol.180 , pp. 635-643
    • Morton, D.L.1    Eilber, F.R.2    Holmes, E.C.3
  • 137
    • 77957723967 scopus 로고    scopus 로고
    • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8? T cell dysfunction in melanoma patients
    • Fourcade J, Sun Z, Benallaoua M et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8? T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186
    • (2010) J Exp Med , vol.207 , pp. 2175-2186
    • Fourcade, J.1    Sun, Z.2    Benallaoua, M.3
  • 138
    • 79953859155 scopus 로고    scopus 로고
    • Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients
    • Leong SP, Zuber M, Ferris RL et al (2011) Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. J Surg Oncol 103:518-530
    • (2011) J Surg Oncol , vol.103 , pp. 518-530
    • Leong, S.P.1    Zuber, M.2    Ferris, R.L.3
  • 139
    • 77954058743 scopus 로고    scopus 로고
    • Chemotherapy resistance abrogation in metastatic melanoma
    • Tawbi HA, Buch SC (2010) Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 8: 259-266
    • (2010) Clin Adv Hematol Oncol , vol.8 , pp. 259-266
    • Tawbi, H.A.1    Buch, S.C.2
  • 140
    • 58149396712 scopus 로고    scopus 로고
    • Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694
    • Tarhini AA, Stuckert J, Lee S et al (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27:38-44
    • (2009) J Clin Oncol , vol.27 , pp. 38-44
    • Tarhini, A.A.1    Stuckert, J.2    Lee, S.3
  • 141
    • 77957331901 scopus 로고    scopus 로고
    • Correlation of molecular human leukocyte antigen typing and outcome in highrisk melanoma patients receiving adjuvant interferon
    • Gogas H, Kirkwood JM, Falk CS et al (2010) Correlation of molecular human leukocyte antigen typing and outcome in highrisk melanoma patients receiving adjuvant interferon. Cancer 116:4326-4333
    • (2010) Cancer , vol.116 , pp. 4326-4333
    • Gogas, H.1    Kirkwood, J.M.2    Falk, C.S.3
  • 142
    • 32644454916 scopus 로고    scopus 로고
    • Prognostic significance of autoimmunity during treatment of melanoma with interferon
    • Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718
    • (2006) N Engl J Med , vol.354 , pp. 709-718
    • Gogas, H.1    Ioannovich, J.2    Dafni, U.3
  • 143
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 144
    • 79960403316 scopus 로고    scopus 로고
    • Cytotoxic T-lymphocyte-associated antigen-4
    • Salama AK, Hodi FS (2011) Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 17:4622-4628
    • (2011) Clin Cancer Res , vol.17 , pp. 4622-4628
    • Salama, A.K.1    Hodi, F.S.2
  • 145
    • 0023888654 scopus 로고
    • Hypothyroidism after treatment with interleukin-2 and lymphokineactivated killer cells
    • Atkins MB, Mier JW, Parkinson DR et al (1988) Hypothyroidism after treatment with interleukin-2 and lymphokineactivated killer cells. N Engl J Med 318:1557-1563
    • (1988) N Engl J Med , vol.318 , pp. 1557-1563
    • Atkins, M.B.1    Mier, J.W.2    Parkinson, D.R.3
  • 146
    • 34247868145 scopus 로고    scopus 로고
    • Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
    • Yurkovetsky ZR, Kirkwood JM, Edington HD et al (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13:2422-2428
    • (2007) Clin Cancer Res , vol.13 , pp. 2422-2428
    • Yurkovetsky, Z.R.1    Kirkwood, J.M.2    Edington, H.D.3
  • 147
    • 33745989541 scopus 로고    scopus 로고
    • Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
    • Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171
    • (2006) J Clin Oncol , vol.24 , pp. 3164-3171
    • Moschos, S.J.1    Edington, H.D.2    Land, S.R.3
  • 148
    • 33947423447 scopus 로고    scopus 로고
    • Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b
    • Wang W, Edington HD, Rao UN et al (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531
    • (2007) Clin Cancer Res , vol.13 , pp. 1523-1531
    • Wang, W.1    Edington, H.D.2    Rao, U.N.3
  • 149
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma untreated brain metastases and other solid tumours: A phase 1 dose-escalation trial
    • Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 150
    • 84873098095 scopus 로고    scopus 로고
    • Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring
    • Abstr 8533
    • Tarhini AA, Edington H, Butterfield LH et al (2012) Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring. Proceedings. J Clin Oncol 30:Abstr 8533
    • (2012) Proceedings. J Clin Oncol , vol.30
    • Tarhini, A.A.1    Edington, H.2    Butterfield, L.H.3
  • 151
    • 84856069688 scopus 로고    scopus 로고
    • Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
    • Tarhini AA, Cherian J, Moschos SJ et al (2012) Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30:322-328
    • (2012) J Clin Oncol , vol.30 , pp. 322-328
    • Tarhini, A.A.1    Cherian, J.2    Moschos, S.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.